Mont-Saint-Guibert (Belgium), Sept. 1 (Korea Bizwire) – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robelga SRL / Robert Taub On August 27, 2021, Nyxoah received a transparency notification from Robelga SRL following the passive downward crossing by [...]
Mont-Saint-Guibert, Belgium, Aug. 31 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced its unaudited condensed consolidated interim financial statements for the first half of 2021. Highlights $97.8 million Nasdaq IPO gross [...]
Mont-Saint-Guibert, Belgium, Aug. 27 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Rita Johnson-Mills as an Independent Director to its Board of Directors. Robert Taub, Chairman of the Board of Directors [...]
Mont-Saint-Guibert, Belgium, Aug. 11 (Korea Bizwire) — Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after [...]
Mont-Saint-Guibert (Belgium), July 19 (Korea Bizwire) – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On July 16, 2021, Nyxoah received a transparency notification from BNP Paribas Asset Management SA following the [...]
Mont-Saint-Guibert (Belgium), July 14 (Korea Bizwire) –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On July 12, 2021, Nyxoah received a transparency notification from Deerfield Partners, L.P. following the acquisition of voting securities or voting rights [...]
Mont-Saint-Guibert (Belgium), July 9 (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of 435,250 new shares on July 9, 2021 pursuant to (i) a capital increase in connection with Nyxoah’s initial public offering in the [...]
Mont-Saint-Guibert, Belgium, July 8 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing on July 7, 2021 of its initial public offering in the United States (the “Offering”) of 2,835,000 ordinary shares at [...]
Mont-Saint-Guibert (Belgium), July 7 (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of 2,835,000 new shares on July 7, 2021 pursuant to a capital increase in connection with Nyxoah’s initial public offering in the United States. Share capital: EUR 4,295,126.64 Total number of securities carrying voting rights: 25,002,609 (all ordinary shares) Total number of voting rights (= denominator): 25,002,609 (all relating to ordinary shares) Number [...]
Mont-Saint-Guibert, Belgium, July 2 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the pricing of its initial public offering in the United States (the “Offering”) of 2,835,000 ordinary shares at a [...]